369 related articles for article (PubMed ID: 28129699)
1. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.
Polsinelli VB; Shah SJ
Expert Opin Pharmacother; 2017 Mar; 18(4):399-409. PubMed ID: 28129699
[TBL] [Abstract][Full Text] [Related]
2. Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).
Tschöpe C; Birner C; Böhm M; Bruder O; Frantz S; Luchner A; Maier L; Störk S; Kherad B; Laufs U
Clin Res Cardiol; 2018 Jan; 107(1):1-19. PubMed ID: 29018938
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.
Konstantinou DM; Chatzizisis YS; Giannoglou GD
Pharmacol Ther; 2013 Nov; 140(2):156-66. PubMed ID: 23792088
[TBL] [Abstract][Full Text] [Related]
4. Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.
Tannenbaum S; Sayer GT
Curr Opin Cardiol; 2015 May; 30(3):250-8. PubMed ID: 25807227
[TBL] [Abstract][Full Text] [Related]
5. Heart failure with preserved ejection fraction: a clinical dilemma.
Komajda M; Lam CS
Eur Heart J; 2014 Apr; 35(16):1022-32. PubMed ID: 24618346
[TBL] [Abstract][Full Text] [Related]
6. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M
JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
Nochioka K; Sakata Y; Shimokawa H
Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin-aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. A meta-analysis of 13 randomized controlled trials.
Zhang Q; Chen Y; Liu Q; Shan Q
Herz; 2016 Feb; 41(1):76-86. PubMed ID: 26272273
[TBL] [Abstract][Full Text] [Related]
9. Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.
Fukuta H; Goto T; Wakami K; Ohte N
Heart Fail Rev; 2017 Nov; 22(6):775-782. PubMed ID: 28702858
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison.
Bonsu KO; Arunmanakul P; Chaiyakunapruk N
Heart Fail Rev; 2018 Mar; 23(2):147-156. PubMed ID: 29411216
[TBL] [Abstract][Full Text] [Related]
11. Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
Shah SJ
J Cardiovasc Transl Res; 2017 Jun; 10(3):322-336. PubMed ID: 28681133
[TBL] [Abstract][Full Text] [Related]
12. Heart failure with preserved ejection fraction: present status and future directions.
Yoon S; Eom GH
Exp Mol Med; 2019 Dec; 51(12):1-9. PubMed ID: 31857581
[TBL] [Abstract][Full Text] [Related]
13. Beta-blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve-HR trial).
Palau P; Seller J; Domínguez E; Gómez I; Ramón JM; Sastre C; de la Espriella R; Santas E; Miñana G; Chorro FJ; González-Juanatey JR; Núñez J
Clin Cardiol; 2020 May; 43(5):423-429. PubMed ID: 32073676
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Heart Failure with Preserved Ejection Fraction.
Ilieșiu AM; Hodorogea AS
Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin-aldosterone system inhibitors in heart failure.
Shearer F; Lang CC; Struthers AD
Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings.
Patel HC; Hayward C; Dungu JN; Papadopoulou S; Saidmeerasah A; Ray R; Di Mario C; Shanmugam N; Cowie MR; Anderson LJ
J Card Fail; 2017 Jul; 23(7):517-524. PubMed ID: 28434933
[TBL] [Abstract][Full Text] [Related]
17. β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration.
Yamamoto K
J Cardiol; 2015 Sep; 66(3):189-94. PubMed ID: 25881728
[TBL] [Abstract][Full Text] [Related]
18. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M; Friberg L
JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
[TBL] [Abstract][Full Text] [Related]
19. Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.
Fukuta H; Goto T; Wakami K; Kamiya T; Ohte N
Heart Fail Rev; 2021 Jan; 26(1):165-171. PubMed ID: 32743714
[TBL] [Abstract][Full Text] [Related]
20. Heart failure with preserved ejection fraction: uncertainties and dilemmas.
Ferrari R; Böhm M; Cleland JG; Paulus WJ; Pieske B; Rapezzi C; Tavazzi L
Eur J Heart Fail; 2015 Jul; 17(7):665-71. PubMed ID: 26079097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
